Inovio Pharmaceuticals (INO) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
2 Jul, 2026Risk factors and disclosures
High degree of risk due to clinical, regulatory, and commercialization uncertainties; risks detailed in the prospectus, supplements, and incorporated filings.
Forward-looking statements subject to significant uncertainties, including regulatory outcomes, trial results, and financial needs.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Inovio Pharmaceuticals
- Net loss narrowed as FDA review of INO-3107 advances and cash runway extends into 2027.INO
Q2 2026 - INO-3107 demonstrated significant surgery reduction in RRP and leads a robust DNA medicine pipeline.INOCorporate presentation
- INO-3107 shows strong efficacy in RRP, with regulatory review and commercial launch plans advancing.INOJefferies Global Healthcare Conference 2026
- All proposals passed; focus shifts to INO-3107 FDA approval and commercial launch in 2026.INOAGM 2026
- INO-3107 BLA under FDA review; FY2025 net loss narrows, cash runway into Q4 2026.INOQ4 2025
- INO-3107 showed 81% efficacy in reducing surgeries, with cash runway into Q3 2025.INOQ3 2024
- INO-3107 BLA delayed to mid-2025; Q2 net loss $32.2M, cash runway into Q3 2025.INOQ2 2024
- Net loss narrowed and cash runway extends into Q1 2026 as INO-3107 advances toward BLA submission.INOQ1 2025
- INO-3107 BLA submission on track, net loss narrows, and cash runway extends into 2026.INOQ4 2024